CTLA4 and colitis: Immunotherapy-related colitis (irC) can pose life-threatening risks and is among the most common irAE associated with anti-CTLA-4 and dual anti-PD-1/anti-CTLA-4 (Som et al., 2019; Khoja et al., 2017).